340 related articles for article (PubMed ID: 25935863)
1. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
von Scholten BJ; Hansen TW; Goetze JP; Persson F; Rossing P
J Diabetes Complications; 2015 Jul; 29(5):670-4. PubMed ID: 25935863
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
Zobel EH; von Scholten BJ; Lindhardt M; Persson F; Hansen TW; Rossing P
J Diabetes Complications; 2017 Jan; 31(1):162-168. PubMed ID: 27769801
[TBL] [Abstract][Full Text] [Related]
3. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
[TBL] [Abstract][Full Text] [Related]
4. The effect of liraglutide on renal function: A randomized clinical trial.
von Scholten BJ; Persson F; Rosenlund S; Hovind P; Faber J; Hansen TW; Rossing P
Diabetes Obes Metab; 2017 Feb; 19(2):239-247. PubMed ID: 27753201
[TBL] [Abstract][Full Text] [Related]
5. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
6. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
von Scholten BJ; Lajer M; Goetze JP; Persson F; Rossing P
Diabet Med; 2015 Mar; 32(3):343-52. PubMed ID: 25251901
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
[TBL] [Abstract][Full Text] [Related]
8. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
[TBL] [Abstract][Full Text] [Related]
9. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Tonneijck L; Smits MM; Muskiet MH; Hoekstra T; Kramer MH; Danser AH; Ter Wee PM; Diamant M; Joles JA; van Raalte DH
Diabetes Care; 2016 Nov; 39(11):2042-2050. PubMed ID: 27585605
[TBL] [Abstract][Full Text] [Related]
10. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
[TBL] [Abstract][Full Text] [Related]
11. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
13. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
[TBL] [Abstract][Full Text] [Related]
14. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study.
Moriya T; Tanaka S; Sone H; Ishibashi S; Matsunaga S; Ohashi Y; Akanuma Y; Haneda M; Katayama S
J Diabetes Complications; 2017 Feb; 31(2):473-478. PubMed ID: 27396240
[TBL] [Abstract][Full Text] [Related]
15. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
16. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
Imamura S; Hirai K; Hirai A
Tohoku J Exp Med; 2013 Sep; 231(1):57-61. PubMed ID: 24064677
[TBL] [Abstract][Full Text] [Related]
17. Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study.
Rosenlund S; Hansen TW; Andersen S; Rossing P
Diabet Med; 2015 Nov; 32(11):1445-52. PubMed ID: 26331364
[TBL] [Abstract][Full Text] [Related]
18. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
[TBL] [Abstract][Full Text] [Related]
19. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
von Scholten BJ; Davies MJ; Persson F; Hansen TW; Madsbad S; Endahl L; Jepsen CH; Rossing P
J Diabetes Complications; 2017 Jul; 31(7):1164-1168. PubMed ID: 28462892
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.
Brocco E; Velussi M; Cernigoi AM; Abaterusso C; Bruseghin M; Carraro A; Sambataro M; Piarulli F; Sfriso A; Nosadini R
J Nephrol; 2001; 14(6):461-71. PubMed ID: 11783602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]